Posted by Michael Wonder on 30 Apr 2021
FDA approves treatment for chronic kidney disease
30 April 2021 - Approval is first to cover many causes of disease.
Today, the U.S. FDA approved Farxiga (dapagliflozin) oral tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalisation for heart failure in adults with chronic kidney disease who are at risk of disease progression.
